Comparative Pharmacology
Head-to-head clinical analysis: LONITEN versus RAUVAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LONITEN versus RAUVAL.
LONITEN vs RAUVAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Minoxidil is a potassium channel opener that causes direct vasodilation of peripheral arteries. It reduces peripheral vascular resistance and blood pressure by hyperpolarizing vascular smooth muscle cells via activation of ATP-sensitive potassium channels.
Rauval (rauwolfia serpentina alkaloids) depletes catecholamines and serotonin from peripheral sympathetic nerve endings and the brain by binding to and inhibiting vesicular monoamine transporters (VMAT), thus reducing sympathetic outflow. This leads to vasodilation, decreased peripheral vascular resistance, and reduced blood pressure.
10 mg orally twice daily, titrated to 40 mg twice daily for hypertension; for heart failure, start at 2.5-5 mg orally twice daily, max 20 mg twice daily.
1.5 mg orally once daily, increased to 3 mg per day if needed. Maximum dose 6 mg per day.
None Documented
None Documented
Terminal elimination half-life: 4.2 hours (range 3.5–5.5); clinically, half-life extends to 14–23 hours after chronic dosing due to drug accumulation.
Terminal elimination half-life is 7-10 hours in normal renal function; prolonged to 14-20 hours in renal impairment, requiring dose adjustment.
Renal: 85% (12% unchanged, 73% as glucuronide conjugates); biliary/fecal: 3%
Renal excretion of unchanged drug accounts for 60-70% of elimination; biliary/fecal excretion accounts for 20-30%.
Category C
Category C
Antihypertensive
Antihypertensive